157 related articles for article (PubMed ID: 9328156)
1. Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
Kylmälä T; Taube T; Tammela TL; Risteli L; Risteli J; Elomaa I
Br J Cancer; 1997; 76(7):939-42. PubMed ID: 9328156
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
[TBL] [Abstract][Full Text] [Related]
3. Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer.
Kylmälä T; Castrén-Kortekangas P; Seppänen J; Ylitalo P; Tammela TL
Pharmacol Toxicol; 1996 Sep; 79(3):157-60. PubMed ID: 8884875
[TBL] [Abstract][Full Text] [Related]
4. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
Elomaa I; Kylmälä T; Tammela T; Viitanen J; Ottelin J; Ruutu M; Jauhiainen K; Ala-Opas M; Roos L; Seppänen J
Int Urol Nephrol; 1992; 24(2):159-66. PubMed ID: 1385586
[TBL] [Abstract][Full Text] [Related]
6. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.
Cresswell SM; English PJ; Hall RR; Roberts JT; Marsh MM
Br J Urol; 1995 Sep; 76(3):360-5. PubMed ID: 7551847
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group.
Kylmälä T; Tammela T; Risteli L; Risteli J; Taube T; Elomaa I
Eur J Cancer; 1993; 29A(6):821-5. PubMed ID: 7683480
[TBL] [Abstract][Full Text] [Related]
8. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
[TBL] [Abstract][Full Text] [Related]
9. The effect of two different doses of oral clodronate on pain in patients with bone metastases.
Arican A; Içli F; Akbulut H; Cakir M; Sencan O; Samur M; Açikgöz N; Demirkazik A
Med Oncol; 1999 Sep; 16(3):204-10. PubMed ID: 10523801
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Robertson AG; Reed NS; Ralston SH
J Clin Oncol; 1995 Sep; 13(9):2427-30. PubMed ID: 7666103
[TBL] [Abstract][Full Text] [Related]
11. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Heidenreich A; Hofmann R; Engelmann UH
J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
[TBL] [Abstract][Full Text] [Related]
12. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Jagdev SP; Purohit P; Heatley S; Herling C; Coleman RE
Ann Oncol; 2001 Oct; 12(10):1433-8. PubMed ID: 11762816
[TBL] [Abstract][Full Text] [Related]
14. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer and bone metastases. The effect of clodronate.
Kylmälä T
Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
[No Abstract] [Full Text] [Related]
16. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.
Taube T; Kylmälä T; Lamberg-Allardt C; Tammela TL; Elomaa I
Eur J Cancer; 1994; 30A(6):751-8. PubMed ID: 7917532
[TBL] [Abstract][Full Text] [Related]
17. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study.
Varenna M; Zucchi F; Ghiringhelli D; Binelli L; Bevilacqua M; Bettica P; Sinigaglia L
J Rheumatol; 2000 Jun; 27(6):1477-83. PubMed ID: 10852274
[TBL] [Abstract][Full Text] [Related]
18. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.
Adami S; Mian M
Recent Results Cancer Res; 1989; 116():67-72. PubMed ID: 2527401
[TBL] [Abstract][Full Text] [Related]
19. Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
Kanis JA; Powles T; Paterson AH; McCloskey EV; Ashley S
Bone; 1996 Dec; 19(6):663-7. PubMed ID: 8968035
[TBL] [Abstract][Full Text] [Related]
20. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
